The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
=== Genetically engineered cages === Macromolecular cages can also be formed synthetically using biomolecules. Protein cages can be genetically engineered, and the outside of the cage can be tailored with synthetic polymers, which is known as protein-polymer conjugation. Preformed polymer chains can be attached to the surface of the protein using chemical linkers. Polymerization can also occur from the protein surface, and the polymer can also be bound to the surface of protein cages via electrostatic interactions. The purpose of this modification is to make synthetic protein cages more biocompatible; this post synthetic modification makes the protein cage less susceptible to an immune response and stabilizes the cage from degradation from proteases. Virus-like protein (VLP) cages have also been synthesized and recombinant DNA technology is used to form non-native virus-like proteins. The first reported case of the formation of non-native VLP constructs into a capsid-like structure utilized a functionalized gold core for nucleation. The self-assembly of the VLP was initiated by the electrostatic interaction of the functionalized gold nanoparticles which is similar to the interaction of a native virus with its nucleic acid component. These viral protein cages have potential applications in biosensing and medical imaging. DNA origami is another strategy to form macromolecular cages or containers. In one case, a 3D macromolecular cage with icosahedral symmetry (resembling viral capsids) was formed based on the synthetic strategy in 2D origami.
Menthol's ability to chemically trigger the cold-sensitive TRPM8 receptors in the skin is responsible for the well-known cooling sensation it provokes when inhaled, eaten, or applied to the skin. In this sense, it is similar to capsaicin, the chemical responsible for the spiciness of hot chilis (which stimulates heat sensors, also without causing an actual change in temperature). Menthol's analgesic properties are mediated through a selective activation of κ-opioid receptors. Menthol blocks calcium channels and voltage-sensitive sodium channels, reducing neural activity that may stimulate muscles. Some studies show that menthol acts as a GABAA receptor positive allosteric modulator and increases GABAergic transmission in PAG neurons. Menthol has anesthetic properties similar to, though less potent than, propofol because it interacts with the same sites on the GABAA receptor. Menthol may also enhance the activity of glycine receptors and negatively modulate 5-HT3 receptors and nAChRs. Menthol is widely used in dental care as a topical antibacterial agent, effective against several types of streptococci and lactobacilli. Menthol also lowers blood pressure and antagonizes vasoconstriction through TRPM8 activation. Menthol inhalation was demonstrated to improve cognitive decline in Alzheimer's disease mouse models. It also produced immunostimulatory effects in the mice.
== Degradation == Prostacyclin, which has a half-life of 42 seconds, is broken down into 6-keto-PGF1, which is a much weaker vasodilator. A way to stabilize prostacyclin in its active form, especially during drug delivery, is to prepare prostacyclin in alkaline buffer. Even at physiological pH, prostacyclin can rapidly form the inactive hydration product 6-keto-prostaglandin F1α.
H2O2 + Fe(III)-E → H2O + O=Fe(IV)-E(.+) H2O2 + O=Fe(IV)-E(.+) → H2O + Fe(III)-E + O2 Here Fe()-E represents the iron center of the heme group attached to the enzyme. Fe(IV)-E(.+) is a mesomeric form of Fe(V)-E, meaning the iron is not completely oxidized to +V, but receives some stabilising electron density from the heme ligand, which is then shown as a radical cation (.+). As hydrogen peroxide enters the active site, it does interact with the amino acids Asn148 (asparagine at position 148) and His75, causing a proton (hydrogen ion) to transfer between the oxygen atoms. The free oxygen atom coordinates, freeing the newly formed water molecule and Fe(IV)=O. Fe(IV)=O reacts with a second hydrogen peroxide molecule to reform Fe(III)-E and produce water and oxygen. The reactivity of the iron center may be improved by the presence of the phenolate ligand of Tyr358 in the fifth coordination position, which can assist in the oxidation of the Fe(III) to Fe(IV). The efficiency of the reaction may also be improved by the interactions of His75 and Asn148 with reaction intermediates. The decomposition of hydrogen peroxide by catalase proceeds according to first-order kinetics, the rate being proportional to the hydrogen peroxide concentration. Catalase can also catalyze the oxidation, by hydrogen peroxide, of various metabolites and toxins, including formaldehyde, formic acid, phenols, acetaldehyde and alcohols. It does so according to the following reaction:
Sources: en.wikipedia.org
nonsense mutation Also point-nonsense mutation. A type of point mutation which results in a premature stop codon in the transcribed mRNA sequence, thereby causing the premature termination of translation, which results in a truncated, incomplete, and often non-functional protein.
=== 2021: Olympic gold, second ATP Finals title === Zverev began his season in February with the ATP Cup, where he represented Germany with Jan-Lennard Struff, Kevin Krawietz and Andreas Mies to reach the semi-finals. In his first Grand Slam tournament appearance at the 2021 Australian Open, he defeated Marcos Giron, Maxime Cressy, Adrian Mannarino and Dušan Lajović. His run ended in the quarterfinals, where he lost to the eventual champion and world No. 1 Novak Djokovic. In March his first tournament was in Rotterdam, where he lost in the first round to Kazakh Alexander Bublik. He continued his performances in Acapulco, where he won his 14th ATP title by defeating Stefanos Tsitsipas in the final. At the tournament in Miami, he lost in the second round to Finland's Emil Ruusuvuori. At his first tournament in 2021 on clay in Monte Carlo, Zverev finished in the third round, losing to David Goffin. In Munich, he reached the quarterfinals, losing to the 107th ranked tennis player in the world, Ilya Ivashka. At the Madrid Open, Zverev defeated Rafael Nadal, Dominic Thiem, and Matteo Berrettini en route to his fourth Masters 1000 title and 15th career title. At the same tournament, he also reached his first semifinal in doubles at a Masters 1000, partnering with compatriot Tim Pütz, but withdrew from the match. He reached the quarterfinals of the Masters 1000 in Rome, losing to eventual tournament winner Rafael Nadal. In his second Grand Slam tournament of the year – in Paris, where he was seeded No.
In 1905, the Cossack hosts experienced deep mobilization of their menfolk amid the fighting of the Russo-Japanese War in Manchuria and the outbreak of revolution within the Russian Empire. Like other peoples of the empire, some Cossack stanitsas voiced grievances against the regime by defying mobilization orders, or by making relatively liberal political demands. But these infractions were eclipsed by the prominent role of Cossack detachments in stampeding demonstrators and restoring order in the countryside. Subsequently, the wider population viewed the Cossacks as instruments of reaction. Tsar Nicholas II reinforced this concept by issuing new charters, medals, and bonuses to Cossack units in recognition for their performance during the Revolution of 1905. In September 1906, reflecting the success of the Cossacks in putting down the Revolution of 1905, Polkovnik (Colonel) Vladimir Liakhov was sent to Iran to command the train and lead the Persian Cossack Brigade. Liakhov had led a Cossack squad in putting down the revolution in the Caucasus, and following the outbreak of the Constitutional Revolution in Iran he was sent to Tehran to recognize the Cossack Brigade as a force for power to the shah. The Persian Cossack Brigade had not been paid for months and proved to be dubious loyalty to the House of Qajar during the Constructional revolution while its Russian officers were uncertain what to do with Russia itself in revolution.
Glutathione S-transferase Mu 4 is an enzyme that in humans is encoded by the GSTM4 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase that belongs to the mu class. The mu class of enzymes functions in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding the mu class of enzymes are organized in a gene cluster on chromosome 1p13.3 and are known to be highly polymorphic. These genetic variations can change an individual's susceptibility to carcinogens and toxins as well as affect the toxicity and efficacy of certain drugs. Diversification of these genes has occurred in regions encoding substrate-binding domains, as well as in tissue expression patterns, to accommodate an increasing number of foreign compounds. Multiple transcript variants, each encoding a distinct protein isoform, have been identified. In the August 2009 issue of Oncogene journal, researchers at Huntsman Cancer Institute (HCI) at the University of Utah demonstrated that expression levels of GSTM4 could predict response to chemotherapy in patients with Ewing sarcoma. The study found that patients who did not respond to chemotherapy had high levels of GSTM4.
== Success rate == Candidates for a new drug to treat a disease might, theoretically, include from 5,000 to 10,000 chemical compounds. On average about 250 of these show sufficient promise for further evaluation using laboratory tests, mice and other test animals. Typically, about ten of these qualify for tests on humans. A study conducted by the Tufts Center for the Study of Drug Development covering the 1980s and 1990s found that only 21.5 percent of drugs that started Phase I trials were eventually approved for marketing. In the time period of 2006 to 2015, the success rate was 9.6%. The high failure rates associated with pharmaceutical development are referred to as the "attrition rate" problem. Careful decision making during drug development is essential to avoid costly failures. In many cases, intelligent programme and clinical trial design can prevent false negative results. Well-designed, dose-finding studies and comparisons against both a placebo and a gold-standard treatment arm play a major role in achieving reliable data.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.